Hair Loss: What Are the Treatment Options?

At this point, this particular scene is so common it has become a cliche…

You wake up one morning and, as you refresh yourself, you spot a heart-stopping site…Your hair has started falling out! And for no apparent reason!

Luckily for you though, we live in the 21^st century, a time where hair loss is no longer necessarily something to resign oneself to. Even more lucky for you is the range of medical, dietary, and lifestyle-related options that can aid your bid to reclaim your locks!

Common Hair Loss Treatments

Let’s start by looking at the more common solutions for this issue, which is commonly associated with the notorious illness that is alopecia.

Commercial Pharmaceuticals

While hair transplants are an increasing trend, they are a bit on the pricey end for most people. As a result, most regular folks faced with hair loss tend to seek other avenues for a solution. The pharmaceutical industry is one such avenue, with more and more companies wading into the hair loss market.

At present, one of the more popular solutions is the over-the-counter drug minoxidil (more commonly known as “Rogaine”), which comes in either pill form or as a topical liquid. Minoxidil, which can also be used to deal with hypertension, is arguably the main drug used by both men and women to combat alopecia.

You also have Finasteride, a prescription-only pill that is known to produce satisfactory results. For the best results, this drug requires consistent doses (usually one pill a day) for prolonged periods. Finasteride users have to be patient because it can take north of 90 days for any noticeable changes.

Transplant

Arguably the most buzzworthy solution to hair-related issues thanks to popularization by celebrities, the transplant is all the rage these days, and for good reason. But what are they all about?

Well, a hair transplant can either be in the form of follicular unit transplantation (FUT) or a follicular unit extraction (FUE), both of which involve the introduction of hair-producing follicles to balding spots. The major difference is that the latter does not require the patient to undergo surgical follicular removal, which gives it a much shorter recovery period than the former. There are many that often wonder if a hair transplant is a painful process. It’s important for you to do your research and also consult with your doctor so they can put you at ease. But the short answer is that there will be discomfort, but it is just the usual pain expected from any invasive procedure, even if your pain threshold is low, you can still manage.

Dietary and Lifestyle Solutions

Your lifestyle and diet can (and usually do) have a direct impact on the health of your hair.

Smoking, for example, has been noted as a silent killer of hair follicles. So, if you do, you might want to take a break from lighting up.

Some shampoos, ironically, can also do MUCH more harm than good. You should be very careful when picking out a brand of shampoo, as some sulfate-based products can cause severe scalp irritation, which can then lead to hair thinning and balding.

Other lifestyle tips to combat hair loss include regular scalp massages and minimization of stress.

As for what you eat, be sure to take in foods that are rich in iron, omega-3 fatty acids, proteins, and vitamins like biotin. Biotin is found in all kinds of foods including egg yolk, cauliflower, whole grains, organ meats, nuts, and many more.

Thanks to the above solutions, hair loss is no longer the “death sentence” it used to be just a few decades ago. Nowadays you can employ one or a combination of these (and many other) solutions to save your beloved hair. What’s even more exciting is that science continues to discover more and more potential solutions, giving, even more, hope to what was once a hopeless situation.

Of course, consulting your doctor is always a wise move before you take the plunge.

The NHS Prioritises Mental Health Care For Millions of Kids

How To Protect Your Child's Mental Health

Thanks to NHS fast track services, well over 2.4 million children and adolescents now have access to mental health assistance in schools and colleges, helping to meet record demand. The NHS deployment is already a year ahead of schedule, with over 500 teams approved prior to the April 2023 deadline, and millions of people able to get care when they need it.

Around 4,700 schools and colleges throughout the UK now have NHS mental health support teams, with 287 experienced teams providing care to youngsters diagnosed with anxiety, despair, and other prevalent mental health issues.

A total of 112 new teams are in training and will begin in the coming year, with another 104 commencing in 2022–23, bringing the total number of teams to more than 500 across the country. Claire Murdoch, the Head of Mental Health Care in England, said the services will provide a safety net for many young people who are struggling or need some help during a visit to Richard Challoner School in Surrey to see how an NHS mental health team has supported children throughout the disruption of the last two years.

Over the last year, a total of 650,000 children and young people came into contact with mental health NHS services, up from 534,000 before the pandemic. Experts hope that intervening early may avoid difficulties from progressing into major mental health problems, with health officials warning that the pandemic’s isolation and turmoil can be exacerbated by variables such as social media pressure. Children’s lives have been enormously disrupted over the last two years, said Claire Murdoch, NHS National Mental Health Director. That is why NHS staff and partner organisations have worked hard on the ground to fast track the roll out of hundreds of mental health teams throughout schools and give encouragement to millions of pupils, a year ahead of schedule.

NHS mental health support groups are now in place in about 4,700 schools and colleges throughout the UK, willing to listen to any fears or issues that children may have, and Claire says she would encourage everyone, whether a teacher, parent, or child, to seek assistance before things get out of hand.

As part of its plan to support a staggering 345,000 children and young people with mental health care by 2024, the NHS Long Term Plan would continue investing in not just mental health support but mental health services more broadly. Since its inception, the local mental health team serving Richard Challoner School and other Kingston schools has helped hundreds of students, with approximately 250 recommended so far.

A Year 10 student at Richard Chancellor School was one of the students who received assistance. He found the sessions quite beneficial, and it inspired him to consider how he might make himself feel good about everything, boosting his overall attitude, he stated.

One of the parents, who requested anonymity, said they were so grateful for the valuable assistance and the excellent preventative feedback it gave. Their son was genuinely suffering, and the regular support helped him learn simple and practical ideas and tactics to improve his welfare and psychological health, both in the immediate issues he was experiencing at school and to help him see the future more clearly.

Teachers and GPs can refer students to the teams, as well as the young people themselves in certain cases, such as Gloucestershire, through a texting service. Experts in the teams will provide one-on-one and group counselling to children while also working to raise mental health awareness among the entire school community through parent training and teacher workshops.

Those who are having problems are given help coping, including courses on sleeping better. Teachers are also given wellness sessions by the teams. In March 2020, the first 59 school mental health teams went to work. The last two years have been extremely trying for children and young people, so it’s crucial they can seek support as soon as possible, said Gillian Keegan, Minister for Mental Health.

The £79 million investment has helped the NHS to speed up the implementation of mental healthcare groups and extended community services, allowing tens of thousands of more youngsters to receive care. They have also launched a call for evidence to get input from people of all ages in order to inform a fresh 10-year mental health plan that will keep the country in better mental health, and Gillian encourages everyone to contribute. Probable mental health disorders among children aged six to sixteen in England have increased from one in nine in 2017 to one in six in 2021.

Since 2017, one in every five children aged six to sixteen has had their mental health deteriorate. Accelerating mental health support teams in schools is just one component of a larger package of NHS support available to children and young people as they cope with the pandemic’s effects. The NHS has established 24-hour emergency support lines, as well as face-to-face, telephone, and digital consultations, so that problems can be discovered and assistance provided faster.

Zimmer Biomet Debuts First-of-its-Kind Artificial Intelligence Capabilities for Omni Suite Intelligent Operating Room

Zimmer Biomet Holdings, Inc., a global medical technology leader, introduced the availability of new artificial intelligence (AI) capabilities within Omnia Suite, an intelligent operating room (OR) designed to optimize surgical workflow and procedural efficiency by automating manual tasks and streamlining unnecessary technology and redundant hardware. The new AI feature uses cameras to automatically recognize and timestamp key OR workflow milestones, including patient entry and exit, door count, the start and stop of anesthesia, surgery and cleaning. Surgical teams are guided through a process to help optimize OR workflow based on real-time access to workflow metrics.

“Omni Suite is more than just another manual integration solution – it is a smart system designed to work with OR staff throughout the procedure,” said Robert Kraal, Vice President and General Manager, Connected Health at Zimmer Biomet. “Now, with this new feature, surgical teams can utilize and rely on Omni Suite’s AI capabilities to optimize OR workflow. By providing data points that have been historically captured manually, if at all, surgical teams can improve OR workflow and minimize manual activities, allowing more time for patient care.”

Omni Suite’s AI feature further expands the AI capabilities of ZBEdge, a suite of integrated smart, digital and robotic technologies designed to deliver transformative data-powered clinical insights with the goal of improving patient outcomes. Last month, ZBEdge added powerful predictive analytics capabilities with WalkAI, an AI model to predict post-operative gait (walking) speed recovery progress after hip or knee surgery.

“Omni Suite’s latest feature further enhances the value and utility of the Omni Suite platform while adding AI capabilities to strengthen our ZBEdge Connected Intelligence Suite,” said Ivan Tornos, Chief Operating Officer, Zimmer Biomet. “Omni Suite, along with the smart, digital and robotic solutions that make up ZBEdge, allow us to create value innovation that unlocks data-driven insights to enhance the surgical experience for surgeons, care teams and patients.”

About the Company

Zimmer Biomet is a global medical technology leader with a comprehensive portfolio designed to maximize mobility and improve health. We seamlessly transform the patient experience through our innovative products and suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence.

With 90+ years of trusted leadership and proven expertise, Zimmer Biomet is positioned to deliver the highest quality solutions to patients and providers. Our legacy continues to come to life today through our progressive culture of evolution and innovation.

Above Half of Early COVID-19 Cases Have Issues 2 Years Later

WHO And Kuaishou Technology Make COVID-19 Data Available

As per a new study that may be one of the oldest and largest on record to track people with protracted COVID, the vast majority of the people who were hospitalised with COVID-19 early in the outbreak had lingering symptoms even two years after their first infection.

The recently published study indicated that two years later, 55% of patients reportedly had at minimum one COVID-19 symptom. This was an improvement over six months following infection, when 68 percent of those infected developed signs. Researchers from the China-Japan Friendship Hospital examined the medical data of 1,192 people who were admitted to Jin Yin-tan Hospital in Wuhan, China, and released between January 7 and May 29, 2020.

The researchers checked back with the patients six months, a year, and two years after they were discharged to get their subjective evaluation of their symptoms. More objective medical tests, such as lung function tests, CT scans, and six-minute walk tests, were also used to evaluate the individuals.

Two years later, the participants’ health was significantly worse. Those with lasting COVID-19 symptoms reported pain, weariness, sleeping troubles, and mental health issues. Long-term lung issues were more common in patients who received higher-level breathing support while in the hospital.

Participants who had persistent symptoms also visited the doctor more frequently than before the outbreak. They had a tougher time exercising and had a lower quality of life overall. The majority had returned to work, but it’s unclear whether they were performing at the same pace as before they became ill. China-Japan Friendship Hospital’s Dr. Bin Cao, one of the study’s co-authors, thinks that the findings would motivate clinicians to check up with patients who have COVID-19 infection years after the primary infection. In a news release, Cao stated that there is a compelling need to provide continuous assistance to a considerable proportion of patients who have had COVID-19 and to investigate how vaccinations, developing treatments, and variations affect long-term healthcare outcomes.

There are some limitations to the research. The results were not compared to those who had been hospitalised for causes other than COVID to see if they, too, experienced persistent problems. They compared the inpatient group to people who had never taken COVID-19 in the community; both groups had health issues a year later, but about half as many as the hospitalised group.

Another problem was that the study only featured one hospital, so the findings may not apply to all COVID-19 patients in hospitals. Patients were frequently detained in hospitals for longer during the pandemic than they are now, which could affect how long somebody had symptoms. Because the study was conducted early in the outbreak, it’s unknown whether similar results would be seen in people who were ill with later coronavirus strains or in people who had been inoculated.

Dr. Devang Sanghavi, a critical care expert at Mayo Clinic in Jacksonville, Florida, who studies long-term COVID and deals with long-term COVID patients, hopes that future long COVID studies will incorporate vaccination status. Sanghavi, who was not part of the study, stated that the only thing he knows he can safely provide to COVID users is vaccination. If they evaluate the occurrence of signs of long COVID in non-vaccinated and vaccinated patients, they find that vaccinated patients have fewer severe symptoms and are less likely to have long COVID.

Sanghavi, like the authors, expects that the findings will help politicians recognise the need for funding long-haul research and expanding infrastructure to better handle long-haul patients. According to studies, there could be huge numbers of people with extended COVID. Sanghavi explained that, for now, these patients appear to be an afterthought.

The analysis estimates how many individuals will require assistance. He is not sure if people tried to get a schedule for a primary care visit, but in many regions, it can take weeks or even months. And that’s only for a basic check-up; forget about the extended COVID. That’s a lot more time, he remarked. More physicians will also have to be taught about how to help those with lengthy COVID, as per Sanghavi. One expert says that the healthcare system is unprepared for the kind of patient influx that this illness will entail.

Dr. Kristine Erlandson, an associate professor of medicine and a communicable diseases specialist at the University of Colorado, has been recruiting patients for a research on COVID-19’s long-term effects. The project is part of the RECOVER experiment at the National Institutes of Health.

Long COVID has piqued the interest of so many individuals, Erlandson said, that her co-workers still haven’t had to publicise the study; there seems to be a waiting list.

The findings of the current study match what personnel at long-haul clinics are witnessing. This is comparable to what one hears from patients in the United States, who claim they are still experiencing symptoms two years later, especially in the first wave of pandemic patients. This is something experts have been hearing anecdotally for some time, so it’s always wonderful to have it written. Erlandson, who has not been involved in the research, said individuals in her clinic share similar symptoms, the most common of which are sleeping problems and weariness.

She stressed that COVID-19 symptoms do not require hospitalisation, and she expects that future research will determine how long non-hospitalized people are experiencing effects. Some of the research subjects improved after a year, but then deteriorated after two years, according to Erlandson.

Such extended trials are intriguing because they show that there is no progressive improvement. In terms of growth, people fluctuate, she said. Erlandson said she’ll be interested to see if the individuals improve after the two years or if COVID-19 turns out to be a debilitating disease. Certain conditions can be treated by doctors, but there is no cure for long COVID.

Unless they can get some form of treatment, she is concerned that it will have a long-term impact on impairment and ability for some people.

New Director of Data Analytics Elevates Noridian’s Statistical Capabilities

Noridian Healthcare Solutions, LLC (Noridian), a leader in developing solutions for federal, state and commercial health care programs, has hired Leslie DiOrio to lead the data analytics department. As director, DiOrio will broaden the team’s abilities across company departments to strategically utilize data analytics to accurately predict workloads and decrease costs for customers. In addition, DiOrio’s team will support the medical policy, claims management and provider enrollment teams and help develop medical review strategies.

“Data analytics is essential to Noridian providing the best solutions and service to our customers because it helps identify where our capabilities are in the organization and how to leverage those skills to operate efficiently and develop impactful strategies,” says Troy Aswege, senior vice president of operations at Noridian. “I am thrilled for Leslie to join our team because she’s a great leader and understands the technical challenges payers and providers deal with and how data analytics can solve those issues.”

The data analytics department will collaborate with the IT division to implement technology that will leverage data to eliminate waste and streamline processes across the company. As a result, the team will improve the customer experience and increase cost savings.

DiOrio has more than 15 years of experience with commercial health care programs and extensive experience in data analytics. Prior to joining Noridian, she worked at Blue Cross Blue Shield of Massachusetts in a variety of roles. A graduate of New York University and UMass Amherst, DiOrio has an MBA from the Isenberg School of Management and is a certified professional coder (CPC). She resides in the Boston area with her husband and two children.

Premier Orthopaedics Announces Partnership with HOPCo to Create Value-Based Musculoskeletal Care Platform in Pennsylvania

Premier Orthopaedics, one of the largest musculoskeletal practices in Pennsylvania and the United States, has announced it is partnering with Healthcare Outcomes Performance Company (HOPCo), the national leader in musculoskeletal practice and clinical outcomes management solutions and the largest orthopedic value-based care organization in the country. This partnership will develop unique clinically integrated partnerships with musculoskeletal practices, physicians, health systems, and payors throughout Pennsylvania and the surrounding regions.

Premier Orthopaedics will be empowered with HOPCo’s proven clinical, quality, outcomes, and claims analytics infrastructure to drive performance, growth, and value-focused musculoskeletal market transformation. Utilizing HOPCo’s proprietary care management platform, software tools, and analytics, the partnership will provide value-based health care solutions that improve care outcomes, patient access, health equity, and the patient experience.

“The landscape of orthopedic and spine care is shifting rapidly. Both payors and patients have placed an increased emphasis on outcomes and proven value,” said Dr. Jeffrey Malumed, President of Premier Orthopaedics. “We knew that HOPCo has spent more than a decade leading the shift to value-based care and has a proven model in multiple regions with multiple provider groups. Their expertise and infrastructure will allow us to be the driving force for change in a very dynamic market.”

Premier Orthopaedics is comprised of over 200 care providers treating the entire spectrum of musculoskeletal disorders. The physicians of Premier Orthopaedics have served the Greater Philadelphia region for over 30 years across 28 practice locations, 17 physical therapy locations, four MRI facilities, urgent care centers, and surgical facilities throughout Southeastern Pennsylvania.

“Premier Orthopaedics has been a vital part of their community for the past three decades,” said Dr. Wael Barsoum, President and Chief Transformation Officer of HOPCo. “Their dedication to transforming the market and fostering alignment with key stakeholders around value-based care will help ensure that patients across the region will benefit from such efforts for decades to come.”

“When we began evaluating our opportunities for growth, we knew that we needed to partner with an organization that provided unique offerings,” said Matthew O’Malley, CEO of Premier Orthopaedics. “HOPCo’s proven track record of optimizing operational performance, leveraging their robust and dedicated infrastructure combined with unmatched practice analytics and improving alignment between physician practices, payors and health systems was a natural fit for Premier Orthopaedics.”

Premier Orthopaedics is the newest addition to HOPCo’s growing national MSK market transformation platform. In the last 12 months, HOPCo has entered into three practice partnerships in Florida, multiple practice partnerships in Nevada, and additional partnerships in Michigan and Arizona. Additionally, HOPCo has partnered with health systems and physician practices in more than 30 states and continues to partner with payors across the US in advanced value-based care programs.

HOPCo has also developed the country’s first state-wide MSK-focused population health program in Arizona, as well as a state-wide clinically integrated network for value-based care in Florida.

How the Country You Live in Could Affect Your Out-of-Pocket Healthcare Costs

Healthcare costs have been on the rise across the globe in a trend that’s unlikely to slow down anytime soon. However, your out-of-pocket healthcare expenses may vary drastically depending on which country you live in. For example, people living in Australia or in Mediterranean countries may pay twice as much for medical treatments as residents of New Zealand. But why does the country you live in affect your out-of-pocket healthcare expenses? This article discusses the factors that affect healthcare costs in different countries and breaking down the data from website comparethemarket.com.au

Allocations of Funds

High-to-middle-income countries focus more on funding healthcare out of budget and diminishing their dependence on external funding. This causes a decline in people’s reliance on out-of-pocket expenses. These countries also tend to invest in poverty education and overall economic growth, which offers more jobs in the healthcare sector and results in healthier and safer societies.

In low-to-middle income countries, where the allocations are not so carefully planned, the majority of the population simply can’t afford primary or private healthcare. Here, the inequities between the two income margins are even more pronounced, as those living in poverty face even greater difficulties paying their medical expenses out-of-pocket. On top of that, in these countries, fewer people are employed in the medical sector, which means higher costs of medical treatments.

Health Care Structure

The lack of a structured medical system also affects how much people pay out-of-pocket for their treatment. This was more than evident during the recent health crisis caused by the global coronavirus pandemic. The residents of many low-income countries were unsure where to turn with their symptoms, causing a delay in their treatment and higher medical expenses.

In countries where an efficient system was already in place, the crisis was handled better because people were less hesitant to ask for help. They knew where they could safely receive treatment for any condition or injury suffered.

Lack of Transparency

Whether people can afford to pay for medical care privately is irrelevant if they don’t know just how much their expenses will be. The lack of transparency in both government-funded and private treatment cost structures means that they can’t plan how much they should allocate from private funding. This results in unexpected out-of-pocket expenditure in emergencies. Your aim is to always have transparency regarding any service you use so you can have peace of mind and costs don’t run rampant.

Population Demographics

Lastly, the average age of the population in each country will also affect the costs of medical treatments. In countries where the average age of the population is on the higher side, people require more extensive care, and the government has fewer funds to allocate for individual patients. Consequently, they’ll have to pay more for it out of their own pockets.

There are many reasons why where you live affects how much you’ll pay out-of-pocket for your medical care. The disproportionate allocation of funds by the government seems to be the number one reason why residents of certain countries are expected to cash out more, especially for non-urgent treatments.

Countries with an older population may also struggle to provide enough funds for healthcare. Lack of information and a transparent healthcare structure is another factor that contributes significantly and, because of that, people in certain countries pay more for healthcare.

COVID-19 Boosters May Be Much More Significant Than Before

The Biden administration estimates that up to 100 million additional individuals could contract COVID-19 in the fall and winter due to diminishing immunity and a coronavirus that appears to become more contagious with every new variant. According to specialists, it is critical that as many people as possible receive COVID-19 vaccination booster doses. It’s also an excellent time to obtain a second booster if one is eligible.

According to the US Centers for Disease Control and Prevention, only about a third of eligible Americans roughly half of the total population have received their first booster dose. Only about 10 million people have had a second booster, which is only prescribed for adults 50 and over, as well as those who are mildly to severely immunocompromised and are 12 or older.

The CDC urges people to be “up-to-date” on COVID-19 immunizations, which entails obtaining boosters when needed, but still deems someone “completely vaccinated” if they have had at least their initial vaccination set. However, a top Biden administration official was more forthright this week: a third shot is required for all adults. Individuals can best defend themselves against COVID-19 by getting vaccinated, and at least three injections are required, as per the official.

According to Dr. Peter Marks, head of the US Food and Drug Administration’s Center for Biologics Evaluation and Research, getting additional Americans vaccinated against COVID-19 might have a major impact in terms of case numbers. He told the American Medical Association that he was “a little worried” about the COVID-19 pandemic’s trajectory.

Marks said it is critical that we get the third dose to the half — or slightly more than half — of Americans who have only gotten two doses. He adds that it might make some difference going forward from here, and it might create a change now that we are nearing another COVID-19 wave.

The current increase of COVID cases is nothing compared to the first Omicron spike, although according to Johns Hopkins University, the US is experiencing 71,577 new cases each day.

The Northeast region of the United States has the highest case rates and the strongest booster uptake. As per CDC data, nearly half of Vermont’s population is completely vaccinated and boosted, as are more than 40% of the people in Maine, Rhode Island, Connecticut, and Massachusetts.

However, in the South, where less than a quarter of the population is completely vaccinated and boosted, cases are beginning to rise. Only about 1 in 5 people in North Carolina, Alabama, and Mississippi have taken their booster dose.

Who is getting boosters and who is not?

A booster dose is available to everyone in the United States aged 12 and up. For adolescents aged 12 to 17, only the Pfizer/BioNTech vaccine is offered as a booster.

Adults who received the mRNA vaccination as a first dose are entitled to a booster dosage 5 months following the first series. Johnson & Johnson vaccine recipients are qualified for a booster shot two months following their initial vaccination.

According to CDC data, booster vaccination rates are much higher in elderly groups in the United States, which is consistent with larger immunisation trends. However, over two out of every five seniors over the age of 65, as well as more than three out of every five individuals, have not received either of their booster injections.

According to studies, people who receive three doses of an mRNA vaccination have a lower rate of COVID-related acute medical visits and hospitalisation than those who receive only two doses. A booster effectively protects against more severe sickness, even with the extremely infectious Omicron strain. Scientists are still determining whether an extra vaccine dose would assist younger age groups. Pfizer and BioNTech have requested emergency use authorisation for youngsters 5-11. Hopefully, that will be addressed in the near future, Marks added.

Fourth doses: new research

According to a study released recently, a 4th dose of Moderna or Pfizer/mRNA BioNTech’s COVID-19 vaccine—which is already okayed for people 50 and older in the United States—holds promise and offers a “significant” boost in protection at comparable or better levels than a third dose.

In January, nearly seven months after their initial booster, the researchers gave trial participants with a median age of 70.1 years a half dose of the Moderna vaccination or a complete dose of the Pfizer vaccine in a random assortment. The second booster did not appear to have any detrimental consequences. Arm discomfort and weariness were the most common complaints.

The immune response following the booster was likewise stronger at day 14 than it was at day 28 after three doses of either the Pfizer or Moderna COVID-19 vaccine.When comparing the mRNA vaccines, the researchers found that Moderna’s fourth dose worked somewhat better than Pfizer’s, although it’s unknown why. Both showed a “substantial fold change” in protective antibodies, according to the researchers. After the fourth dose, T-cell reactions improved as well.

Antibodies are the initial line of defence against viruses, preventing them from invading cells. T lymphocytes arrive later and kill contaminated cells. T-cells cannot fight off minor infections, but they can stop infections from becoming serious.

The study concludes that fourth-dose COVID-19 mRNA booster vaccinations are well absorbed and enhance cellular and humoral immunity. Peak responses after the fourth dose were comparable to, if not superior to, peak reactions after the third dose. The study also found that some participants who had higher antibody levels prior to receiving the fourth dose of the COVID-19 vaccination only had “minimal” boosting. Those who had previously been infected with COVID-19 had a similar restricted reaction. According to the authors, this shows that a fourth vaccine dose may have a cap or maximum effect.

The study didn’t look into neutralisation of the Omicron version in particular. Two previous Israeli studies found that giving a fourth vaccine dose at least four months following the third dose lowered hospitalisation and mortality rates from COVID-19. With this fourth dose, the decrease in hospitalizations and deaths lasted a lot longer.

Vaccines and boosters of a new generation

Marks anticipates that the next phase of COVID-19 vaccines, which he expects to be available within a year or two, will be even better at defending people against the absolute range of COVID variants and evoking a stronger immune reaction.

In late June, the FDA’s vaccine advisory group will convene to assess vaccine data, particularly monovalent (which targets a single variation) plus bivalent vaccines that could target the original strain of the virus plus another.

They don’t know how much farther the infection will mutate over the next few months, Marks explained. But one may not have an option; if we want to create the hundreds of millions of dosages needed for a booster campaign, we’ll have to start in early July or even earlier.

According to Marks, the FDA committee may also examine whether a second booster should be advised in the fall for the wider populace or for certain groups. Some doctors say they’ve heard from individuals who want to put off getting a booster until the winter to receive better coverage. Marks advises against waiting for a booster, especially if the person hasn’t had COVID-19 recently.

He explained that this is because it will be another four, five, or six months before they receive their next booster. Even though an autumn and winter surge is expected, cases are already on the rise, and people who have only had two mRNA doses are at risk. Marks explained, just because we have enough circulating COVID-19, he would advise them to attempt to obtain that third dose to build up the resistance.

Sentinel U Launches Advanced Practice Series to Help Advanced Practice Learners Hone Their Skills

Sentinel U, a provider of web-based simulation education technology solutions for nursing schools, hospital systems and healthcare professionals, has launched its newest virtual simulation, Advanced Practice Series.

Designed specifically for advanced practice learners, the new simulation series authentic virtual encounters enable nurse practitioner, physician assistant/associate (PA) and nursing students to hone the clinical judgement and decision-making skills necessary to make accurate diagnoses and establish proper plans of care. The robust virtual simulation series offers 55 unique patient encounters within 11 specialty areas, including typical and complex adult and pediatric care, women’s health, mental health, cardiology, oncology, and gerontology.

“We are excited to expand the depth and breadth of our virtual simulations and clinical experiences to now include simulations specifically for the advanced practice market,” said Jeffrey Caplan, president of Sentinel U. “This new simulation series can be used after the required 720 hours to meet clinical hours, allowing learners to practice and refine essential diagnostic and care competencies.”

The Advanced Practice Series provides learners with an authentic and immersive real-world experience. Each module introduces a diverse patient population from a variety of ethnicities and backgrounds exhibiting common complaints in various clinical areas.

“The Advanced Practice Series offers engaging patient scenarios designed to ensure that learners are thoroughly prepared for any situation they may encounter in practice,” said Sentinel U Vice President of Clinical Learning Resources Laura Gonzalez, Ph.D., APRN, CNE, CHSE-A, ANEF, FAAN. “Just like our products created for nursing students, we tapped the knowledge of highly respected working professionals to help us develop this new virtual simulation series.”

With genuine scenarios created by subject matter experts, learners will advance through each clinical encounter while reviewing the patient inquiry, history and physical (H&P) examination, and review of systems (ROS) within the electronic health record (EHR). Additionally, the modules reinforce knowledge of international classification of diseases (ICD), current procedural terminology (CPT), and healthcare common procedure coding system (HCPCS) codes for billing consideration.

The Advanced Practice Series features EMPOWER, Sentinel U’s self-led, asynchronous standardized debrief experience designed to allow learners to critically analyze their performance. EMPOWER guides learners through seven reflective steps: explore, misconceptions, practice standards, opportunities, wins, evaluate, and reflect and review. Its purpose is to arm learners with the knowledge, skills and aptitudes to formulate sound clinical judgments in future practice situations ensuring they are competent and confident when facing an actual clinical situation.

Educators will appreciate that each module includes a faculty guide, feedback and rationales, along with a dashboard with an evaluative report. The assignments align academically with competencies for PA professionals adopted by the American Academy of Physician Assistants (AAPA), Accreditation Review Commission on Education for the Physician Assistant (ARC-PA), National Commission on Certification of Physician Assistants (NCCPA) and Physician Assistant Education Association (PAEA); the National Organization for Nurse Practitioner Faculties (NONPF) role-specific competencies; Accreditation Council for Graduate Medical Education (ACGME) core competencies; and American Association of Colleges of Nursing (AACN) Essentials for advanced-level nursing education.

About Sentinel U
Sentinel U is a leading provider of health care simulations and learning innovations for nursing students and healthcare professionals. Its authentic virtual simulations and clinical experiences are the best practice in engaging learners in real-world scenarios to gain unparalleled clinical judgement and critical thinking experience. A division of American Sentinel College of Nursing & Health Sciences at Post University, Sentinel U is an industry leader in virtual simulation education for more than 130,000 learner experiences worldwide.

Gerresheimer And Portal Team Up To Treat Without Needles

Gerresheimer AG is broadening its range of cutting-edge drug delivery platform technologies. Gerresheimer, a major provider of healthcare and beauty solutions as well as drug delivery systems for pharma, biotech, and cosmetics, has invested in Portal Instruments, a creator of next-generation needle-free drug delivery applications based in the United States. The partners hope to improve patient outcomes by altering the delivery of injectable drugs. This is especially important for those with chronic health conditions.

Portal creates technology that allows for needle-free, high-speed subcutaneous administration of medicine as well as patient and medical care giver adherence monitoring throughout the treatment journey via connectivity. Portal Instruments was founded in MIT’s Bio Instrumentation Lab and is situated in Cambridge, Massachusetts.

Portal Instruments is working on cutting-edge technology. They will make a substantial contribution to increasing patient quality of life and also make treatment efficiency a success by combining their knowledge of medication delivery technology and manufacturing. These findings will also aid in the reduction of healthcare expenditures , according to Gerresheimer CEO Dietmar Siemssen. The investment is yet another step in the formula G strategic process. It will improve their ability to provide their clients with distinctive and inventive options. In collaboration with Portal, they will increase the client base as well as their existing IP and product portfolio.

They are excited to be collaborating more closely with Gerresheimer, a well-known market leader in medication delivery systems, stated CEO of Portal Instruments, Patrick Anquetil. Gerresheimer provides extensive development and manufacturing know-how and a strong network of worldwide pharma and biotech customers as a solutions provider as well as a platform integrator. Their scaling efforts will be aided by this financing. Portal’s expansion goals will be boosted by Gerresheimer’s monetary assistance. Gerresheimer purchased a minority investment in the company, with the opportunity to grow it in the future. Portal’s Board of Directors will include a Gerresheimer representative.

The needle-free injector and cartridge developed by Portal are part of a medication delivery platform for biologics and biosimilars that has been finished and made available to biopharma partners. Unlike several automatic injectors on the market, Portal’s needle-free technology can inject the very same quantity in less than a second. At the same time, this novel injection technique has been found to be less painful than conventional needle and syringe injections. And the injector is much more than a drug delivery system: owing to its connectivity, patients and medical care providers can track compliance and customise illness management. Gerresheimer will contribute to the development of new technology, as well as manufacture the reused injector and provide pharmaceutical cartridges.

Gerresheimer: An Introduction

Gerresheimer is a worldwide partner for pharmaceutics, biotechnology, healthcare, and cosmetics, offering a wide range of pharmaceutical and cosmetic packaging solutions as well as drug delivery systems. From concept to final delivery, the organisation is an inventive solution supplier. Gerresheimer achieves its lofty aims by combining a high degree of innovation with industrial expertise and an emphasis on quality and service. The company relies on a vast international network of research and production centres in Europe, America, and Asia to produce creative and sustainable solutions. With roughly 10,000 employees worldwide, Gerresheimer produces close to its consumers and earned annual revenues of around EUR 1.5 billion in 2021. The company contributes to people’s health and well-being through its products and solutions.

Portal Instruments: An Introduction

With strategic and venture capital backing, Portal Instruments is a privately held medical device firm focused on improving medication delivery. The injector and cartridge that Portal uses are part of a platform for delivering drugs that has been finished and is now available through biopharma partners.